Admedus announces facility agreement with Partners for Growth
26, October, 2017
Admedus Ltd today announced that it has entered into an agreement with Partners for Growth (PFG) for a secured debt facility of up to AUD $10 million. Based in the San Francisco Bay area, PFG is a partnership that provides capital funding debt solutions to private and public technology and life science companies. Read full […]
Admedus TAVR project on track with new IP applications
24, October, 2017
Admedus Ltd today announced that it has submitted IP applications relating to the development of a new Transcatheter Aortic Valve Replacement (TAVR) device. Read the full ASX statement here.
New neck and head cancer treatment a step closer to trials
23, October, 2017
As reported widely across Australian media outlets, Admedus Immunotherapies recently received a $250,000 Government grant from the Advance Queensland Ignite Ideas Fund to support human clinical trials, led by Professor Ian Frazer, of a new vaccine that could be used to treat head and neck cancer. Find a copy of the story on News.com, 7 News or Brisbane Times. Read the full […]
Update on experts’ meeting (advisory board)
13, October, 2017
Posted In: Featured
Recently, at the Admedus advisory board meeting run consecutively with the EACTS annual congress in Vienna, doctors validated the clinical benefits/medical utility and value to patients of our single piece aortic valve (vs. three piece leaflet from the competitors) in both the TAVR and SAVR settings. Our development work in this area continues as we […]
Investor webinar 5 September 2017
1, September, 2017
Admedus Limited (ASX: AHZ) held an investor webinar on 5 September, 2017 to discuss the results of the Company’s Preliminary Final Report (Appendix 4E) for the year ended 30 June 2017. Admedus CEO Wayne Paterson will provide a review of the Company’s year-end performance as well as operational and business highlights.
Admedus announces exclusive supply agreement with 4C Medical
31, August, 2017
Admedus Limited is pleased to announce that it has entered an exclusive supply agreement with 4C Medical Technologies, Inc. (4C Medical), a Minnesota-based developer of minimally invasive therapies for structural heart disease. Read more here.
Sponsorship supports kids with heart disease
15, August, 2017
Admedus Ltd is proud to announce a six-month $20k sponsorship of the HeartKids Education Program which provides vital resources for families of children living with congenital/childhood heart disease. In Australia, congenital/childhood heart disease is the leading cause of death for children under a year old and nearly three thousand babies are born with a heart […]